Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07058441
Active, not recruiting Observational

Clinical and Mechanistic Research on Autogenous Arteriovenous Fistula in Hemodialysis Patients

NCT07058441 · tracked via the Priya Life Science China tracker
Sponsor
Ai Peng
Phase
Observational
Started
2024-10-01
Last updated
2025-07-10

Condition(s) studied

Arteriovenous Fistula Maturation Failure in End-stage Renal Disease

Study summary

This study aims to investigate the long-term clinical outcomes and molecular mechanisms of autogenous arteriovenous fistula (AVF) maturation failure in uremic patients. The primary goal is to develop a precision prediction model integrating clinical, imaging, and biomarker data, while secondary objectives focus on identifying key molecular targets regulating AVF maturation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥18 years 2. Diagnosed with chronic kidney disease stage 5 (ESRD) and scheduled for first-time autogenous AVF creation 3. No severe coagulation disorders or vascular malformations 4. Willing to provide written informed consent 5. Planned hemodialysis at the study center Exclusion Criteria: 1. Previous AVF surgery on the ipsilateral limb 2. Ipsilateral central venous stenosis or significant venous outflow obstruction 3. Active malignancy (except localized non-melanoma skin cancer) 4. Active infection at the surgical site 5. Life expectancy \<1 year 6. Pregnancy or lactation 7. Participation in other interventional trials

Primary outcome measure(s)

  • Arteriovenous fistula maturation failure rate — 6 weeks and 6 months post-surgery
    Failure to meet KDOQI criteria at 6 weeks post-operation (blood flow \<600 mL/min, venous diameter \<6 mm, OR subcutaneous depth \>6 mm) AND inability to sustain hemodialysis (2 sessions/week)

Trial sites (1)

FacilityCityRegionStatus
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital Shanghai China

More Ai Peng trials in China

Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07058441 on ClinicalTrials.gov ↗ ← All trials in China